Yep. They're sleazy like that.They had to change the definition of "vaccine"
Remember?
Yep. They're sleazy like that.They had to change the definition of "vaccine"
Remember?
You know they're doing wonderful things with psychotropics these days.Trump did not make vaccines, Bill Gates and his population-reducing cohorts did.
Good thing they're protected from litigation, eh?
and so do youTrump continues to promote the vaccines to this day, dufus.
Maybe some think experimentation with psychotropics is a good thing but I do not think they should be using Biden as a test subject.You know they're doing wonderful things with psychotropics these days.
no duhand so do you
Not bad, not bad.Maybe some think experimentation with psychotropics is a good thing but I do not think they should be using Biden as a test subject.
All sarcasm aside, Trump's vaccines have, by and large, worked to prevent serious illness and death for millions of people. Trump is right about the vaccines.
no duh
Long Term Follow-Up After Administration of Human Gene Therapy
Products Guidance for Industry
1. The integration activity of the GT product: The biological activity of retroviral vectors4 ( e.g., vectors derived from gammaretrovirus, lentivirus, foamy virus etc.) and transposon elements is imparted by an integration event in the genome. In general, such integration is not directed to specific sites in the human genome, and this raises the potential for disruption of critical host (human) genes at the site of integration, or activation of proto-oncogenes near the integration site(s) and, thereby, the risk for malignancies.
2. Genome editing activity: Genome editing-based GT products impart their biological activity through site-specific changes in the human genome, but may also have off-target effects on the genome (Ref. 2). Similar to integrating vectors, genome editing may produce undesirable changes in the genome ( whether ex vivo or in vivo), with the risk of malignancies, impairment of gene function, etc.
3. Prolonged expression: A GT product where the transgene (therapeutic gene) encodes growth factors, such as vascular endothelial growth factor (VEGF) or proteins associated with cell division such as p53, may raise the potential for unregulated cell growth and malignancies due to prolonged exposure to the therapeutic protein. Similarly, transgenes encoding immune recognition factors may introduce the risk for autoimmune-like reactions ( to self-antigens) upon prolonged exposure. For GT products that carry transcriptional regulatory elements (e.g., microRNA) or immune-modulatory proteins ( e.g., c ytokines) there is also the risk of unknown pleotropic effects, including altered expression of host (human) genes that could result in unpredictable and undesirable outcomes.
4. Latency: When the GT product has the potential for latency, such as a herpes virus, there is the potential for reactivation from latency and the risk of delayed adverse events related to a symptomatic infection.
5. Establishment of persistent infections: GT products that are replication competent viruses and bacteria, such as listeria-based bacterial vectors, have the potential to establish persistent infections in immunocompromised patients leading to the risk of developing a delayed but serious infection. .
thinking that reducing walking deaths by 4 was a great outcome because you missed the fact that you added 9 new driving deaths.
GMO food is better anyway... got the shot , congratulations you are now GMO
I was going to dig this one out later!Long Term Follow-Up After Administration of Human Gene Therapy
Products Guidance for Industry
1. The integration activity of the GT product: The biological activity of retroviral vectors4 ( e.g., vectors derived from gammaretrovirus, lentivirus, foamy virus etc.) and transposon elements is imparted by an integration event in the genome. In general, such integration is not directed to specific sites in the human genome, and this raises the potential for disruption of critical host (human) genes at the site of integration, or activation of proto-oncogenes near the integration site(s) and, thereby, the risk for malignancies.
2. Genome editing activity: Genome editing-based GT products impart their biological activity through site-specific changes in the human genome, but may also have off-target effects on the genome (Ref. 2). Similar to integrating vectors, genome editing may produce undesirable changes in the genome ( whether ex vivo or in vivo), with the risk of malignancies, impairment of gene function, etc.
3. Prolonged expression: A GT product where the transgene (therapeutic gene) encodes growth factors, such as vascular endothelial growth factor (VEGF) or proteins associated with cell division such as p53, may raise the potential for unregulated cell growth and malignancies due to prolonged exposure to the therapeutic protein. Similarly, transgenes encoding immune recognition factors may introduce the risk for autoimmune-like reactions ( to self-antigens) upon prolonged exposure. For GT products that carry transcriptional regulatory elements (e.g., microRNA) or immune-modulatory proteins ( e.g., c ytokines) there is also the risk of unknown pleotropic effects, including altered expression of host (human) genes that could result in unpredictable and undesirable outcomes.
4. Latency: When the GT product has the potential for latency, such as a herpes virus, there is the potential for reactivation from latency and the risk of delayed adverse events related to a symptomatic infection.
5. Establishment of persistent infections: GT products that are replication competent viruses and bacteria, such as listeria-based bacterial vectors, have the potential to establish persistent infections in immunocompromised patients leading to the risk of developing a delayed but serious infection. .
Poor silly guinea pigs
Bump.It's really remarkable how the quote-unquote "vaccines" work. They 'trick' the body into making the 'real' vaccine, is how these things work. The real vaccine is the spike proteins. You can't get enough spike proteins 'injected'. You'd need gallons of the stuff. So instead of that, fortunately, we have the tech to 'trick' the body into making the real vaccine for us. So instead of gallons getting injected into you, to get enough spike protein into you, in order to work as a real vaccine, to provoke the immune system in a predictable manner through the introduction of just the right kind of foreign material; and it's just milligrams.
Hopefully there are no chronic effects, everybody's fingers are crossed on this one, whether they are permitted through partisan expediency to admit it or not, every knowledgeable thinking person knows there remains this looming "known" unknown (aside from the "unknown unknowns" tip of the cap to Mr. Donald Rumsfeld) of chronic effects of this gene therapy drug.
We'll see. We all really hope that we didn't save millions just to lose billions in the future. We're just making the best judgment of the thing with the information we have (evidence) and logic. The effect of the drug wears off, this is a very good sign that the drug completely metabolizes and leaves no trace, or at least that the effect long term will be the same as if it does completely metabolize leaving no (ill) trace.
ITNOTFAOTSAOTHSA. (Prayer)
Why rename it when the process improves?They had to change the definition of "vaccine"